Neurogene Inc. has filed an 8-K form with the SEC on March 24, 2026, detailing its financial results for the fourth quarter of 2026. The filing includes information under Item 2.02, which discusses the results of operations and financial condition. The report indicates that the company has experienced fluctuations in its financial performance, which are typical for the biotechnology sector, particularly in the context of ongoing research and development activities. The filing also includes Item 9.01, which provides financial statements and exhibits related to the earnings release. The company’s address remains the same, located at 535 W 24th Street, 5th Floor, New York, NY 10011. As the company continues to navigate the complexities of the pharmaceutical industry, stakeholders are advised to review the detailed financial statements included in the filing for a comprehensive understanding of the company's current financial health and operational execution. The filing is accessible through the SEC's EDGAR database, providing transparency and regulatory compliance for investors and analysts alike.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.